[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Science/Tech See other Science/Tech Articles Title: Firm Linked to HHS’ Robert Kadlec Poised to Become Exclusive Manufacture of COVID-19 Vaccines A pharmaceutical firm with a dark history and questionable ties to serving ASPR Robert Kadlec is poised to become the exclusive manufacturer of the COVID-19 vaccines now being funded through Trump’s Operation Warp Speed. Trump’s much-ballyhooed “Operation Warp Speed” unveiled in May of this year to produce and deploy a COVID-19 vaccine in the U.S. is shaping up to be yet another scheme to funnel millions of dollars into a singularly corrupt pharmaceutical entity with deep ties to Robert Kadlec, the serving Assistant Secretary for Preparedness and Response (ASPR), who is in charge of the Strategic National Stockpile and is the architect of the legislative edifice which currently governs the nation’s public-private partnership (PPP) approach to health emergencies. The task force’s latest and largest grant was awarded to Maryland-based Novavax, Inc. to cover late-stage testing and manufacturing of their COVID-19 vaccine candidate. Only the sixth company to receive federal funds from Trump’s program, the $1.6 billion infusion is intended to result in the production of 100 million doses by the start of 2021, according to Novavax CEO, Stanley Erck. The other companies favored by Operation Warp Speed include AstraZeneca, which received $1.2 billion last May to develop its AZD1222 vaccine; ModernaTX, Inc. who was awarded nearly $550 million; Merck and IAVI with the relatively paltry sum of $38 million; Sanofi’s Protein Sciences got a little over $30 million and finally, Johnson & Johnson’s subsidiary, Janssen Research & Development, LLC obtained $456 million back in February for its Ad26-based vaccine technology platform, which will ostensibly “maximize the probability of a successful vaccine and rapid deployment within the US and globally.” Of these, the three largest award recipients have direct partnerships to manufacture their vaccines with one company. Emergent Biosolutions, who was awarded a $628 million dollar contract by the Biomedical Advanced Research and Development Authority (BARDA) to provide “manufacturing support” for the delivery of COVID-19 vaccines across the U.S., has entered into agreements with Novavax, Johnson & Johnson and AstraZeneca to provide contract development and manufacturing (CDMO) services. Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||